Literature DB >> 10627547

Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice.

B Mrkic1, B Odermatt, M A Klein, M A Billeter, J Pavlovic, R Cattaneo.   

Abstract

The dissemination of the Edmonston measles virus (Ed-MV) vaccine strain was studied with genetically modified mice defective for the alpha/beta interferon receptor and expressing human CD46 with human-like tissue specificity and efficiency. A few days after intranasal infection, macrophages expressing Ed-MV RNA were detected in the lungs, in draining lymph nodes, and in the thymus. In lymph nodes, large syncytia which stained positive for viral RNA and for macrophage surface marker proteins were found and apoptotic cell death was monitored. In the thymus, smaller syncytia which stained positive for macrophage and dendritic cell markers were detected. Thus, macrophages appear to be the main vectors for dissemination of MV infection in these mice; human macrophages may have a similar function in the natural host. We then compared the pathogenicities of two recombinant viruses lacking the C or V nonstructural proteins to that of the parental strain, Ed-MV. These viruses were less effective in spreading through the lymphatic system and, unlike Ed-MV, were not detected in the liver. After intracerebral inoculation the recombinant viruses caused lethal disease less often than Ed-MV and induced distinctive patterns of gliosis and inflammation. Ed-MV was reisolated from brain tissue, but its derivatives were not. C- and V-defective viruses should be considered as more-attenuated MV vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627547      PMCID: PMC111471          DOI: 10.1128/jvi.74.3.1364-1372.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs).

Authors:  D Hourcade; A D Garcia; T W Post; P Taillon-Miller; V M Holers; L M Wagner; N S Bora; J P Atkinson
Journal:  Genomics       Date:  1992-02       Impact factor: 5.736

2.  Attenuated measles vaccine in children with acute leukemia.

Authors:  A MITUS; A HOLLOWAY; A E EVANS; J F ENDERS
Journal:  Am J Dis Child       Date:  1962-03

3.  Recombinant measles virus requiring an exogenous protease for activation of infectivity.

Authors:  A Maisner; B Mrkic; G Herrler; M Moll; M A Billeter; R Cattaneo; H D Klenk
Journal:  J Gen Virol       Date:  2000-02       Impact factor: 3.891

4.  Acute measles in patients with and without neurological involvement: distribution of measles virus antigen and RNA.

Authors:  T R Moench; D E Griffin; C R Obriecht; A J Vaisberg; R T Johnson
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

5.  Degree and length of viremia in adults with measles.

Authors:  D N Forthal; S Aarnaes; J Blanding; L de la Maza; J G Tilles
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

6.  Viral replication and development of specific immunity in macaques after infection with different measles virus strains.

Authors:  R S van Binnendijk; R W van der Heijden; G van Amerongen; F G UytdeHaag; A D Osterhaus
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

7.  Measles virus editing provides an additional cysteine-rich protein.

Authors:  R Cattaneo; K Kaelin; K Baczko; M A Billeter
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

8.  Measles virus P gene codes for two proteins.

Authors:  W J Bellini; G Englund; S Rozenblatt; H Arnheiter; C D Richardson
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

9.  Infection of monocytes during measles.

Authors:  L M Esolen; B J Ward; T R Moench; D E Griffin
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  42 in total

1.  Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein.

Authors:  W P Duprex; S McQuaid; B Roscic-Mrkic; R Cattaneo; C McCallister; B K Rima
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Measles virus C protein interferes with Beta interferon transcription in the nucleus.

Authors:  Konstantin M J Sparrer; Christian K Pfaller; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 5.  Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.

Authors:  Sallie R Permar; Diane E Griffin; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2006-04

6.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

7.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

8.  Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Ileana Aderca; Mark J Federspiel; Donald J Tindall; John C Morris; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

9.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.